Get the Stockscreener App
20.48
3.98%
-0.85
After Hours:
20.48
Rapport Therapeutics Inc stock is traded at $20.48, with a volume of 184.62K.
It is down -3.98% in the last 24 hours and down -5.84% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$21.33
Open:
$21.31
24h Volume:
184.62K
Relative Volume:
1.14
Market Cap:
$780.18M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+1.69%
1M Performance:
-5.84%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$20.30
$21.97
1-Week Range:
$20.04
$22.24
52-Week Range:
$16.55
$28.08
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
1325 BOYLSTON STREET, BOSTON
Rapport Therapeutics Inc Stock (RAPP) Latest News
Perceptive Advisors LLC Invests $17.40 Million in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Up 6.2% - MarketBeat
(RAPP) Technical Data - Stock Traders Daily
ARCH Venture Management LLC Makes New $86.73 Million Investment in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
ARCH Venture Management LLC Invests $86.73 Million in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Biogen, Alnylam-partnered Camp4 Therapeutics unveils IPO plans - The Business Journals
Rapport Therapeutics Inc. (RAPP) rating initates by TD Cowen - Knox Daily
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 2.4% - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 4.7% - Defense World
Reckitt shares up on report of potential homecare asset sale By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals initiated with a Buy at H.C. Wainwright - TipRanks
Quest Partners LLC Sells 5,882 Shares of iRobot Co. (NASDAQ:IRBT) - Defense World
Sofinnova Investments Inc. Invests $45.39 Million in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading 4.7% Higher - MarketBeat
RNAZ’s Financial Health: Exploring TransCode Therapeutics Inc’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
Trimble and Platform Science pushed hard to get deal done before Vegas meeting - Yahoo Finance
Johnson & Johnson Invests $58.11 Million in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $19.00 - MarketBeat
(RAPP) Trading Advice - Stock Traders Daily
TD Asset Management Inc Takes Position in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
TD Asset Management Inc Invests $2.36 Million in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 5.5% - MarketBeat
The Potential Rise in the Price of Rapport Therapeutics Inc. (RAPP) following insiders activity - Knox Daily
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $21.20 - MarketBeat
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences - GlobeNewswire
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences - StockTitan
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences - Yahoo Finance
Rapport Therapeutics (NASDAQ:RAPP) Trading Up 5.8% - MarketBeat
Market Insights: Rapport Therapeutics Inc. (RAPP)’s Notable Gain of 9.85, Closing at 21.75 - The Dwinnex
Investing in Rapport Therapeutics Inc. (RAPP): What You Must Know - Knox Daily
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $20.40 - Defense World
Rapport Therapeutics to Present at 22nd Annual Morgan - GlobeNewswire
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit - StockTitan
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit - Yahoo Finance
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $20.40 - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4.4% - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading 3.8% Higher - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading Up 2.5% - MarketBeat
(RAPP) Investment Report - Stock Traders Daily
Stifel reiterates buy rating on Rapport Therapeutics shares, keeps $35 PT - Investing.com Canada
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 2.5% - MarketBeat
The 3 Best Healthcare Stocks to Buy in August 2024 - InvestorPlace
Rapport Therapeutics (NASDAQ:RAPP) Shares Up 10.2% - MarketBeat
Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Business Wire
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Down to $18.56 - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Down to $18.56 - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Hits New 12-Month Low at $16.80 - MarketBeat
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update - GlobeNewswire
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update - WDRB
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update - Yahoo Finance
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):